Due to decreased cardiac function and clinical interventions, plasma volume in CHF patients can be divided into two stages: plasma volume overload (PVO) during the onset stage and reduced volume overload following intervention.[10] Drugs recommended by CHF guidelines,[11] such as sodium‐glucose transporter 2 inhibitors, diuretics, and insulin, can impact circulating volume, indirectly affecting lipid concentrations. The gene discussed is INS; the disease is congestive heart failure.